Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA7 | P43166 | 1/20 | 0.46 |
| ▸ | XDH | P47989 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.44 |
| ▸ | GLA | P06280 | 2/20 | 0.44 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.44 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.44 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.44 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516420 | 0.89 | KMT2A (0.53) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| Methyl 3-Chloro-4-Methoxybenzoate SCHEMBL1637523 | 0.83 | KMT2A (0.69) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| Methyl 3-Chloro-4-Methoxybenzoate SCHEMBL31296522 | 0.83 | KMT2A (0.69) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10543265 | 0.82 | S1PR4 (0.56) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL19887442 | 0.81 | TSHR (0.55) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL11928054 | 0.81 | USP2 (0.61) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16981776 | 0.81 | HTT (0.50) | MAPTKMT2ASMN1; SMN2RAB9AMEN1 | |
| SCHEMBL1398536 | 0.81 | MEN1 (0.59) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL16533170 | 0.80 | MAPT (0.49) | MAPTKMT2ASMN1; SMN2NPC1RAB9A | |
| SCHEMBL12800816 | 0.79 | MAPT (0.51) | MAPTKMT2ASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | CAPULUS THERAPEUTICS, LLC (US) | 2023-08-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718628-B2 | SREBP inhibitors comprising a 6-membered central ring | SREBF1, SREBF2, XBP1 | MAPT 354/4885KMT2A 4372/4885SMN1; SMN2 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.